Highlights of NsGene's History

2010

NsGene and Biogen Idec sign new commercialisation and license agreement on Neublastin, a novel therapeutic protein in clinical development for neuropathic pain. Read more. 

2009

Neublastin enters Phase I clinical development as a novel treatment for neuropathic pain. Read more.

NsGene has been granted European Patent No. EP 1 745 069 B1, covering the novel neurotrophic factor Meteorin (NsG33). NsGene has found promising therapeutic effects in models of nervous system disorders including Parkinson’s disease, Huntington’s disease, and neuropathy. Read more.

2008

NsGene’s advanced encapsulated cell biodelivery product for Alzheimer’s disease treatment now successfully implanted in six patients. Read more.

NsGene A/S raises 40 million DKK and appoints Mats Pettersson as new chairman. Read more.

NsGene A/S today announced that its encapsulated cell (EC) biodelivery product, NsG0202, has successfully been implanted into the brains of three patients with Alzheimer’s disease (AD). Read more.

2007

NsGene's Clinical Trial Application (CTA) to start a phase Ib study of NsG0202 for Alzheimer’s disease (AD) has been approved by the Swedish Medical Products Agency (MPA) and the clinical trial will be initiated in March 2008. Read more.

NsGene participates in an EU funded FP6 project looking at Functional Genomics and Neurobiology of Epilepsy - a Basis for New Therapeutic Strategies. Ballerup, February 6, 2007. Read more. 

2006
NsGene’s proprietary neurotrophic factor, Meteorin, will be evaluated by Genzyme for the treatment of motoneuron diseases. Ballerup, November 28, 2006. Read more.

NsGene is granted a Convertible loan from its shareholders of DKK 40 million to be paid in two tranches. Ballerup, November, 2006. Read more. 

Together with nine academic partners, NsGene has been awarded an EU R&D project (INTHER), which could prove valuable for NsGene’s proprietary Encapsulated Cell Biodelivery technology. Ballerup, May 24, 2006. Read more.

2005
Successful development of Neublastin by Biogen Idec triggers milestone payment to NsGene A/S. Ballerup, October 25, 2005. Read more. 

NsGene moves towards clinical development with an additional DKK 30 million and introduces a new investor, Vækstfonden, a Danish Governmental Growth Fund. Ballerup, May 2, 2005. Read more. 

2004
NsGene's proprietary protein Neublastin has advanced into development for the treatment of neuropathic pain. Ballerup, November 2, 2004. Read more.

A US $3 million Michael J. Fox Foundation grant to support a clinical "proof-of-concept" study can yield breakthrough for treatment of Parkinson's disease. Ballerup, July 5, 2004. Read more. 

US Patent Granted for Protein Important for treating Neuropathic Pain.
Ballerup, May 18, 2004. Read more. 

2003
NsGene A/S raises DKK 18 million in a second round of financing from existing investors.
Ballerup, Denmark, December 29, 2003. Read more.

NsGene A/S obtains an exclusive license to encapsulated cell biodelivery technology (EC biodelivery) for the nervous system. Ballerup, Denmark, May 9, 2003. Read more. 

NsGene has been granted US patent No. 6,555,674, JeT promoter. Ballerup, April 29, 2003

NsGene A/S has moved to new premises. Ballerup, January 2, 2003

2002
NsGene is awarded an EU R&D project grant with a budget of € 2.3 million. Ballerup, December 6, 2002

NsGene A/S and ZGene A/S enter a license agreement on kinase technology for development of improved cancer treatments. Ballerup, February 14, 2002

2001
NsGene is awarded an EU R&D project grant as coordinator. Ballerup, November 1, 2001

2000
Biogen Executes License Agreement With NsGene A/S for Novel Neurotrophic Protein.
Ballerup, Denmark, and Cambridge, Massachusetts, U.S.A., December 6, 2000

NsGene A/S and Neurotech S.A. sign collaboration and license agreement to develop Encapsulated Cell Technology for neurological and eye disorders. Ballerup and Paris August 29, 2000

NsGene A/S and Denmark’s Technical University (DTU) sign collaboration and license agreement aimed at identification of new genes, which can be used to develop products for treatment of disorders of the central nervous system. Ballerup, August 14, 2000

NsGene A/S and Biogen, Inc. sign collaborative agreement on novel neurotrophic protein. Ballerup, June 15, 2000

1999
NeuroSearch enters cell and gene therapy by establishment of a new research company, NsGene A/S. Ballerup, December 9, 1999

NeuroSearch A/S is planning to establish a new company to expand the development of cell transplantation for the treatment of diseases of the central nervous system. Ballerup, June 9, 1999